Scientists May Now Know Why GLP-1s Don’t Work For 10% of People

Unlocking the Genetic Mystery Behind GLP-1 Treatment Resistance

A groundbreaking discovery has revealed a genetic quirk affecting the effectiveness of GLP-1 treatments, crucial for managing type 2 diabetes, shedding light on why these medications fail for 10% of patients.

The Breaking Point

A study focusing on an enzyme known as PAM uncovered that certain genetic variants hinder the activation of hormones crucial for GLP-1 effectiveness. This discovery explains why a significant portion of patients experience resistance to GLP-1 based medications like Ozempic, meant to regulate blood sugar levels.

Beneath the Surface

The researchers compared individuals with the PAM variant to those without, discovering that even with high levels of GLP-1, those with the variant showed no increased biological activity in managing blood sugar levels, revealing a surprising resistance.

The Ripple Effect

The implications are vast—potentially leading to genetic tests that can predict treatment efficacy, saving time and resources. Future research might also explore modifying GLP-1 drugs to bypass these genetic hurdles, promising hope for more personalized treatment strategies.